Clinical Trials
26 trialsDalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer
Fudan University
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
Academic and Community Cancer Research United
ROME
Fondazione per la Medicina Personalizzata
BiOnHER
Institut Català d'Oncologia
Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC
Peking University Cancer Hospital & Institute
NeoON
Institut fuer Frauengesundheit
FB-12
NSABP Foundation Inc
Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers
Biocad
Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
easy laugh
Shanghai Pudong Hospital
A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer
Shengjing Hospital
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors
The University of Hong Kong-Shenzhen Hospital
HERMET
University of Kansas Medical Center
NSABP Biospecimen Discovery Project
NSABP Foundation Inc
Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)
Second Affiliated Hospital, School of Medicine, Zhejiang University
Pyramid
Tianjin Medical University Cancer Institute and Hospital
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
IMMUN-HER
Gruppo Oncologico Italiano di Ricerca Clinica
FAVOR
Second Affiliated Hospital, School of Medicine, Zhejiang University
Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer
Shandong Cancer Hospital and Institute
HERACLES
Fondazione del Piemonte per l'Oncologia
NEOADAPT
Midwestern Regional Medical Center